- Home
- BGX vs IPHA Comparison
BGX vs IPHA Comparison
Compare BGX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGX
- IPHA
- Stock Information
- Founded
- BGX 2010
- IPHA 1999
- Country
- BGX United States
- IPHA France
- Employees
- BGX N/A
- IPHA N/A
- Industry
- BGX Trusts Except Educational Religious and Charitable
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- BGX Finance
- IPHA Health Care
- Exchange
- BGX Nasdaq
- IPHA Nasdaq
- Market Cap
- BGX 150.8M
- IPHA 160.1M
- IPO Year
- BGX N/A
- IPHA 2019
- Fundamental
- Price
- BGX $12.16
- IPHA $2.44
- Analyst Decision
- BGX
- IPHA Strong Buy
- Analyst Count
- BGX 0
- IPHA 1
- Target Price
- BGX N/A
- IPHA $11.00
- AVG Volume (30 Days)
- BGX 67.9K
- IPHA 33.6K
- Earning Date
- BGX 01-01-0001
- IPHA 03-27-2025
- Dividend Yield
- BGX 10.34%
- IPHA N/A
- EPS Growth
- BGX N/A
- IPHA N/A
- EPS
- BGX N/A
- IPHA N/A
- Revenue
- BGX N/A
- IPHA $20,831,349.00
- Revenue This Year
- BGX N/A
- IPHA $209.83
- Revenue Next Year
- BGX N/A
- IPHA $83.96
- P/E Ratio
- BGX N/A
- IPHA N/A
- Revenue Growth
- BGX N/A
- IPHA N/A
- 52 Week Low
- BGX $10.69
- IPHA $1.29
- 52 Week High
- BGX $12.44
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- BGX 55.00
- IPHA 73.73
- Support Level
- BGX $11.74
- IPHA $2.22
- Resistance Level
- BGX $12.23
- IPHA $2.34
- Average True Range (ATR)
- BGX 0.15
- IPHA 0.15
- MACD
- BGX 0.04
- IPHA 0.04
- Stochastic Oscillator
- BGX 85.71
- IPHA 84.40
About BGX Blackstone Long Short Credit Income Fund
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategy in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first- and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.